August 2, 2019 06:56 AM EDT
R&D

Ko­re­an biotech sees shares blitzed as its on­colyt­ic virus/Nex­avar com­bo fiz­zles in liv­er can­cer

John Carroll

Editor & Founder

An­oth­er Ko­re­an biotech is in trou­ble this morn­ing.

Sil­la­Jen set off shock waves in the sec­tor af­ter they filed no­tice that they are aban­don­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

A service from the Financial Times